![Qiu Bo Sun](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Qiu Bo Sun
Direttore/Membro del Consiglio presso Beijing Xiangxin Biotechnology Co., Ltd.
Profilo
Qiu Bo Sun has worked as a Member-Supervisory Board at Beijing Xiangxin Biotechnology Co., Ltd.
since 2019.
Posizioni attive di Qiu Bo Sun
Società | Posizione | Inizio |
---|---|---|
Beijing Xiangxin Biotechnology Co., Ltd.
![]() Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | Direttore/Membro del Consiglio | 07/03/2019 |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Beijing Xiangxin Biotechnology Co., Ltd.
![]() Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | Health Technology |
- Borsa valori
- Insiders
- Qiu Bo Sun